The Paris Cardiovascular Research Center

The PARCC (Paris Cardiovascular Research Center, Inserm U970) succeeded in bringing together an important critical mass of basic and clinician scientists, who share a vision and common objectives in the field of cardiovascular diseases. PARCC teams are conducting projects, spanning basic molecular and cellular biology to integrated physiology and pathophysiology, biomarkers, genetics and epidemiology, with the goal of understanding, at a more refined and mechanistic level, disease processes in atherosclerosis, angiogenesis, hypertension, heart failure and sudden cardiac death, and also at the interface between cardiology and oncology. They are developing novel diagnostic and therapeutic strategies. Translational research is an integral part of the mission of the PARCC, in close connection with clinical laboratories and departments of the HEGP hospital.

The PARCC is part of the Université de Paris Cité and of the Institut des sciences cardiovasculaires de l’université de Paris

PARCC’s Tweets

PARCC’s News

Two researchers of the PARCC awarded by the FRM !

Nabila Bouatia-Naji, Jean-Paul Binet Award 2023

Alexandre Loupy, Award from the Fondation Victor et Erminia Mescle 2023

Recent publications

Healthy sleep score changes and incident cardiovascular disease in European prospective community-based cohorts. Nambiema A, Lisan Q, Vaucher J, Perier MC, Boutouyrie P, Danchin N, Thomas F, Guibout C, Solelhac G, Heinzer R, Jouven X, Marques-Vidal P, Empana JP. Eur. Heart J. 2023 Oct 23;ehad657.

See paper

Treatment of severe symptomatic aortic valve stenosis using
non-invasive ultrasound therapy: a cohort study.
Messas E, Ijsselmuiden A,
Trifunović-Zamaklar D, Cholley B, Puymirat E, Halim J, Karan R, van Gameren M,
Terzić D, Milićević V, Tanter M, Pernot M, Goudot G. Lancet. 2023 Nov

See paper

Mission and Objectives

The PARCC is dedicated to experimental disease-oriented research and has as primary aim to catalyze and speed up the production of basic knowledge related to the understanding of the cellular and molecular basis of cardiovascular disease. Its main mission is to maintain an optimal scientific and medical environment in order to promote excellence in cardiovascular translational research. 

Our overall goals for the 2019-2025 period are :
1. to pursue internationally leading laboratory-to-bedside research programs that address fundamental molecular, cellular and physiological mechanisms underlying normal and abnormal cardiovascular function and diseases
2. to maintain a highly collaborative, multi-disciplinary environment which catalyzes the pursuit of imaginative and innovative research programs, based on complementary expertise of the PARCC teams (cell and molecular biology, physiology/pathophysiology, pharmacology, immunology, endocrinology, genetics, epidemiology, imaging)
3. to link these to translational research that improves the prevention, diagnosis and treatment of human cardiovascular disease
4. to establish an optimal environment with cutting-edge technology

5. to undertake high quality research training of non-clinical and clinical scientists

The strategy to achieve our objectives is multifaceted, but is mainly built upon the expertise in basic and clinical translational research of the teams that started internal collaborations, as well as upon strong interactions with the clinical divisions at HEGP (cardiology, cardiovascular prevention, hypertension, medicine, genetics, cardiac and vascular surgery), as well as with the Clinical Investigation Center and the Clinical Research Unit

Key Dates

  • 2005 The first stone of the building is laid at HEGP.


  • 2006 The decision is made by Inserm, Paris Descartes University, Fondation Alain Carpentier and Assistance Publique-Hôpitaux de Paris (the owner of the building) to dedicate the new research building mainly, even though non-exclusively, to cardiovascular research. An international call for recruiting the director of the HEGP Research Center is launched.


  • 2007 Nomination of Alain Tedgui, Inserm Director of research, as director of the HEGP Research Center. Selection of the first 8 research teams of the center, following evaluation of the projects by an international Review Committee.


  • 2008 First site visit of the Evaluation of Research and Higher Education (AERES) committee.


  • 2009 Creation by Inserm and the Paris Descartes University of the Paris- Cardiovascular Research Center (PARCC) with eleven teams approved, including two emerging young AVENIR teams (160 staff members).Official grand opening in the presence of the minister for Research and Higher Education and the minister of Health. .


  • 2014 Re-creation by Inserm and the Paris Descartes University of the Paris- Cardiovascular Research Center, with Alain Tedgui as Director, with 14 research teams approved, including one AVENIR team (250 staff members).


  • 2019 Re-creation by Inserm and Université Paris-Cité of the Paris- Cardiovascular Research Center with Chantal Boulanger, Inserm director of research, as new Director. Thirteen research teams were approved, including one AVENIR team (300 staff members).


  • 2023 Forth site visit of the High Council for Evaluation of Research and Higher Education (Hcéres) in November 2023. Eleven research teams are seeking approval by Inserm and Université Paris-Cité (350 staff members).


  • 2025-2030 New term for the Paris- Cardiovascular Research Center, with Jean-Sébastien Silvestre, Inserm director of research, as new Director.